Table 1.
Demographic and clinical characteristics from the series.
| Patient ID | Gender | 1 Age (Years) | Histologic Subtype | Pathology Details | Location | 2 IRS Group | Risk Group | 3 Upfront Syst. Therapy | Surgery |
|---|---|---|---|---|---|---|---|---|---|
| RMS-01 | F | 19.9 | Alveolar | Myo, Des FOXO+ | Limb | IV | Very high risk | IVADo/IVA | Y (R1) |
| RMS-02 | F | 17.2 | Alveolar | Myo, Act, V | Limb | I | High risk | IVA | Y (R0) |
| RMS-03 | M | 21.6 | Alveolar | Myo, Des | Head & Neck | IIb | Very high risk | IVA/V | Y (R0) |
| RMS-04 | M | 16.7 | Embryonal | Myo, Des | Heart | IV | High risk | EPI-IFOS | Y (R0) |
| RMS-05 | M | 27.4 | Embryonal | Des, Act | Pelvis | IV | High risk | BOMP/EPI | Y (R0) |
| RMS-06 | F | 20.8 | Embryonal | Des, Act | Head & Neck | IV | High risk | BOMP/EPI | Y (R0) |
| RMS-07 | F | 42.2 | Alveolar | Des, Act | Head & Neck | IV | Very high risk | BOMP/EPI | N |
| RMS-08 | M | 20.9 | Alveolar | Myo, Act, V. FOXO+ | Head & Neck | III | Very high risk | VAC/IE | Y (R2) |
| RMS-09 | F | 20.8 | Alveolar | Myo, FOXO− | Head & Neck | IIIa | High Risk | VAC/IE | Y (R0) |
| RMS-10 | F | 44.1 | Spindle cell | Myo, Des. FOXO− | Head & Neck | IIIa | High Risk | IVADo | Y (R1) |
1 Age at diagnosis; 2 Intergroup rhabdomyosarcoma study groups: I—complete resection of primary tumor; II—microscopic residual disease; III—macroscopic residual disease; IV—metastasis from disease onset. 3 Upfront systemic therapy; F—female; M—male; Myo—myogenin; Des—desmin; Act—actin; V—vimentin; FOXO—evidence of FOXO rearrangement; IVADo—ifosfamide, vincristine, actinomycin and doxorubicin; IVA—ifosfamide, vincristine, actinomycin; VAC—vincristine, doxorubicin and cyclophosphamide; IE—ifosfamide and etoposide; EPI/IFOS—epirubicin and ifosfamide; BOMP-EPI—bleomycin, vincristine, methotrexate and cisplatin plus etoposide, cisplatin and ifosfamide; Y—Yes; N—No.